FAQ
Direct answers about the intelligence path.
What is public, what becomes private, what the current work produces, and where the product can go next.
What does Leyoxa sell?
Dental market intelligence for acquisition and expansion: metro screening, submarket opportunity, competitor and practice mapping, and target-specific diligence.
Is this a generic market report?
No. A source-linked report is the first layer. The product should preserve the evidence as the buyer narrows the question toward a submarket, competitor set, practice landscape, or acquisition target.
What can public data answer?
Market structure, population and economic context, growth, establishment counts, observable practice footprints, and comparable signals. It cannot establish private revenue, patient demand, ownership, clinical quality, or acquisition value.
Does market screening require patient information?
No. Metro, submarket, and public practice mapping begin without PHI. Private records are considered only in a separate, authorized target-diligence scope.
What is target-specific diligence?
A bounded, read-only acquisition engagement covering systems, source continuity, migration verification, documentation gaps, record exceptions, limitations, and buyer sign-off.
Does Leyoxa diagnose or write to a PMS?
No. The Care Ledger reports source-linked record states for accountable review. It does not generate diagnoses, recommend care, or write clinical information to a practice system.
What is product direction?
After close, separately authorized portfolio workspaces, morning briefs, and governed agents could build on the same source and ownership model. Those interfaces are direction, not the market-screening deliverable.
Where does Leyoxa work?
The current focus is the United States, followed by Canada. Every geography requires its own source coverage, definitions, dates, and limitations.